72 A newly published study has identified integrins, a family of transmembrane receptors, as key players in the progression and drug resistance of gastric cancer, one of the deadliest malignancies worldwide. The research sheds light on how integrins mediate complex interactions in the tumour microenvironment and influence resistance to chemotherapy, potentially paving the way for novel treatments. The findings were published in the journal Progress in Biophysics and Molecular Biology. Gastric cancer remains a major global health concern, with late-stage diagnosis and poor prognosis being common. While targeted therapies and chemotherapy have improved outcomes for some patients, drug resistance continues to be a significant hurdle. This new study highlights how integrins, specifically certain α and β subunits, contribute to these challenges by regulating tumour growth, metastasis, and immune evasion. The paper outlines the distinct roles of different integrins in gastric cancer. For example, integrin α5 was found to promote cell proliferation and invasion by activating key pathways such as FAK and Src. Another subunit, integrin β1, was linked to enhanced metastatic potential and resistance to drugs like 5-fluorouracil through its activation of the Wnt/β-catenin signalling pathway. These findings suggest that integrins do not merely support tumour development structurally, but actively participate in reprogramming cellular behaviour and drug response. Importantly, integrins were also shown to affect the tumour microenvironment, particularly through interactions with cancer-associated fibroblasts and immune cells. These interactions enable cancer cells to adapt and thrive in hostile conditions, such as low oxygen levels, and facilitate the spread of the disease. The dynamic communication between integrins and surrounding stromal components contributes to a feedback loop that sustains tumour progression and shields cancer cells from treatment. One striking aspect of the study is the evidence that integrin expression can be influenced by external factors such as hypoxia, inflammation, and even Helicobacter pylori infection, which is a known risk factor for gastric cancer. These external stressors appear to upregulate integrin activity, further entrenching drug resistance mechanisms and promoting aggressive disease traits. Current clinical treatments targeting integrins have had limited success due to their widespread expression in healthy tissues, leading to undesirable side effects. However, the authors argue that newer delivery methods, such as integrin-targeted nanoparticles, may overcome this limitation by allowing for precision targeting of cancerous cells. These nanoparticles can deliver chemotherapeutic agents directly to tumours, improving efficacy while minimising systemic toxicity. The findings position integrins as promising candidates for future therapies aimed at not only halting tumour growth but also reversing chemoresistance. Although further studies are needed to validate these findings in clinical settings, this research marks a significant step forward in understanding the molecular underpinnings of gastric cancer and opens new avenues for personalised treatment approaches. With drug resistance presenting one of the greatest obstacles in cancer care, strategies that exploit integrin signalling pathways could redefine the way gastric cancer is treated in the coming years.